Bookmark
Forward
QuickView for pegvisomant (compound)
PubChem Substance
| Name: | pegvisomant |
|---|---|
| PubChem Substance ID: | 3820226 |
| Synonyms: |
B 2036PEG; Somavert; 236101-82-9; Pegvisomant; B 2036; Trovert; B2036; PNU 467MET0435; Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine,168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine) (human), pegylated 191; 218620-50-9.
show more » |
DrugBank
Identification
| Name: | pegvisomant |
|---|---|
| Name (isomeric): | DB00082 |
| Drug Type: | biotech |
| Synonyms: |
GH; GH-N; Growth hormone 1; Somatotropin precursor; Growth hormone; Pituitary growth hormone
|
| Brand: | Somavert (Pfizer Inc) |
| Category: | Anabolic Agents, Hormone Replacement Agents |
| CAS number: | 218620-50-9 |
Pharmacology
| Indication: | Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly. |
|---|---|
| Pharmacology: |
Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like gro...
show more » |
| Mechanism of Action: | Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels. |
| Half Life: | ~6 days |
| Clearance: | 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day] |
| Affected organisms: | Humans and other mammals |
Targets
